Hertig et al., 2010 - Google Patents
Steroid profiling in preeclamptic women: evidence for aromatase deficiencyHertig et al., 2010
View PDF- Document ID
- 1409234395416660355
- Author
- Hertig A
- Liere P
- Chabbert-Buffet N
- Fort J
- Pianos A
- Eychenne B
- Cambourg A
- Schumacher M
- Berkane N
- Lefevre G
- Uzan S
- Rondeau E
- Rozenberg P
- Rafestin-Oblin M
- Publication year
- Publication venue
- American journal of obstetrics and gynecology
External Links
Snippet
OBJECTIVE: Experimental data have revealed the critical role played by 2-methoxy- estradiol, a metabolite of 17β-estradiol, in the pathophysiology of preeclampsia. We used gas chromatography/mass spectrometry to measure a whole panel of hormonal steroids in …
- 150000003431 steroids 0 title abstract description 42
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/743—Steroid hormones
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/88—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving prostaglandins or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hertig et al. | Steroid profiling in preeclamptic women: evidence for aromatase deficiency | |
Berkane et al. | From pregnancy to preeclampsia: a key role for estrogens | |
Frederiksen et al. | Sex-specific estrogen levels and reference intervals from infancy to late adulthood determined by LC-MS/MS | |
Honour | Biochemistry of the menopause | |
Berkane et al. | Abnormal steroidogenesis and aromatase activity in preeclampsia | |
Luisi et al. | Serum allopregnanolone levels in pregnant women: changes during pregnancy, at delivery, and in hypertensive patients | |
Travers et al. | Multiplexed steroid profiling of gluco-and mineralocorticoids pathways using a liquid chromatography tandem mass spectrometry method | |
Conklin et al. | Advancements in the gold standard: Measuring steroid sex hormones by mass spectrometry | |
Hill et al. | Steroid metabolome in plasma from the umbilical artery, umbilical vein, maternal cubital vein and in amniotic fluid in normal and preterm labor | |
Lee et al. | Changes in steroid metabolism among girls with precocious puberty may not be associated with urinary levels of bisphenol A | |
Yuan et al. | An LC-MS/MS analysis for seven sex hormones in serum | |
Johnston et al. | The human fetal adrenal produces cortisol but no detectable aldosterone throughout the second trimester | |
Hertig et al. | New markers in preeclampsia | |
Moon et al. | Cytochrome P450-mediated metabolic alterations in preeclampsia evaluated by quantitative steroid signatures | |
Mezzullo et al. | Female and male serum reference intervals for challenging sex and precursor steroids by liquid chromatography-tandem mass spectrometry | |
van der Veen et al. | Development and validation of a LC-MS/MS method for the establishment of reference intervals and biological variation for five plasma steroid hormones | |
Pařízek et al. | Neuroactive pregnanolone isomers during pregnancy | |
Schiffer et al. | Multi-steroid profiling by UHPLC-MS/MS with post-column infusion of ammonium fluoride | |
Hill et al. | Circulating levels of pregnanolone isomers during the third trimester of human pregnancy | |
du Toit et al. | A high-throughput UPC2-MS/MS method for the separation and quantification of C19 and C21 steroids and their C11-oxy steroid metabolites in the classical, alternative, backdoor and 11OHA4 steroid pathways | |
Desai et al. | Simultaneous measurement of 18 steroids in human and mouse serum by liquid chromatography–mass spectrometry without derivatization to profile the classical and alternate pathways of androgen synthesis and metabolism | |
Ankarberg-Lindgren et al. | A purification step prior to commercial sensitive immunoassay is necessary to achieve clinical usefulness when quantifying serum 17β-estradiol in prepubertal children | |
Pugeat et al. | MANAGEMENT OF ENDOCRINE DISEASE Hyperandrogenic states in women: pitfalls in laboratory diagnosis | |
Sheehan et al. | 5β-Dihydroprogesterone and steroid 5β–reductase decrease in association with human parturition at term | |
Wynn et al. | Changes in maternal pregnane concentrations in mares with experimentally-induced, ascending placentitis |